Access Community Health Network’s Post

28 Medications That Can Impact Your Product Portfolio: Drugs and Conditions Selected in Medicare Negotiations and State Affordability Reviews #Healthcareaffordability concerns arise in national conversations, state regulations, and dinner table conversations. But staying up-to-date in the evolving state prescription drug affordability review boards (#PDABs) is challenging. That's why Innov8 Health Policy, LLC can help you prepare for reviews and assess potential portfolio impacts. In the meantime, check out the 28 medications currently under review. You can't afford NOT to be ready for review.

Utilizing 340B drug pricing program savings, Boston Medical Center Health System has secured nearly $30 million in patient assistance funding to help patients afford their medications, making essential treatments accessible to those who need them most. 💜 Learn more in the full case study: https://lnkd.in/gVC9hn5S. #340B #specialtypharmacy #clearwayhealth #patientassistanceprograms #healthcareequity

Calling all advocacy warriors! The HELP Committee has a hearing scheduled for this Thursday, February 8 and drug pricing is slated to be a topic of conversation. While a focus on drug pricing is appreciated, CSRO knows that the issue cannot be solved without discussing the pharmacy benefit manager (PBM) industry and the need for reform.   When the Finance Committee considered PBM reform last summer, CSRO provided feedback on the importance of delinking PBM income from drug prices and we are now urging the HELP Committee to extend that reform by taking up the DRUG Act. Action Requested: If you have an X account, we ask you to like CSRO’s post and we encourage you to share the post with a “quote” using the following message: "I join CSRO in urging @GOPHELP @HELPCmteDems to discuss the #DRUGAct at Thursday’s hearing as a critical step to lowering drug prices. #PBMReform @SenSanders @SenBillCassidy" #advocacymatters #pbms #patientaccess #drugcosts #healthcare

The industry is still a few years away from knowing the full impact that the Inflation Reduction Act will have on drug prices. But some critical provisions have already impacted drug plan sponsors for 2024. Our team has identified five areas that Medicare Advantage plans should consider when shaping their 2025 Part D strategy > https://owy.mn/47fU7EF #OWActuarial #Medicare #MedicareAdvantage

Ever wondered what to do if your medication needs change? Well, during the Open Enrollment Period, you have the flexibility to switch to a Part D plan tailored to cover your specific medications. This proactive step ensures you're prepared and avoids any unexpected expenses. Do you have any questions for me during this Open Enrollment period? Feel free to send me a DM. Let's work together to align your prescription drug plan with your evolving health journey. www.joinkerri.com #MedicareMaven

Employers this is public information and you need to act! There are solutions as discussed by Antonio. As well as indicated by Antonio, your PBM is basing your formulary and utilization management on how much they receive from various PhRMA companies! Not based on Safety, Efficacy and Cost!!! We can help resolve that issue by managing your utilization based on Safety, Efficacy and Cost to produce Better Outcomes and Lower Cost without changing PBMs. If your PBM or Consultant tells you to continue to allow your PBM to mismanage your utilization at your company's and members' expense and safety, please let me know and I can provide a list of non-conflicted consultants that are not receiving huge revenues from your PBM. Please don't continue to put your company's executives at risk for lawsuits, your company at risk for Dept. of Labor sanctions and most importantly, your members at risk financially and health-wise with your current scenario of allowing your PBM to manage your utilization while profiting from your utilization! Contact me @ [email protected] to discuss. #CEO #CFO #CHRO #Fiduciary #CAA #DoTheRightThing

Some good insight on PBMs here. If you don't understand the issue -- and how they're threatening the entire pharmacy business -- this explains it well!